Bottom line
JAKUX vs DGEIX: the short answer
JAKUX (John Hancock Disciplined Value Global Long/Short Fund) and DGEIX (Global Equity Portfolio) are both mutual funds.
But JAKUX is far broader, holding 292 positions to 6 for DGEIX, so beyond the top names it adds exposure DGEIX doesn't have.
DGEIX is cheaper at 0.25% vs 1.66% — a difference of $141 a year per $10,000 invested.
Over five years, JAKUX returned +14.5% a year vs +11.9% for DGEIX.
Updated Nov 19, 2026
JAKUX vs DGEIX side by side
| JAKUX | DGEIX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | John Hancock | Dimensional |
| Category | Global Stock | Global Stock |
| Expense ratio | 1.66% | 0.25% |
| Annual cost per $10k | $166 | $25 |
| 10-yr cost on $10k (prospectus) | $2,035 | $513 |
| Max front load | — | — |
| 12b-1 fee | 0% | — |
| 1-yr return | +30.0% | +20.2% |
| 5-yr return (annualized) | +14.5% | +11.9% |
| 10-yr return (annualized) | +7.4% | +11.9% |
| Best quarter | — | +21.2% |
| Worst quarter | — | −25.9% |
| Net assets (fund) | $1.3B | $11.4B |
| Number of holdings | 292 | 6 |
| Portfolio turnover | 23% | 6% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
JAKUX and DGEIX share none of their top holdings.
JAKUX top 10
- Fidelity Government Portfolio Fidelity Inv Mmkt Govt-inst — 30.89%
- Labcorp Holdings Inc. — 2.47%
- Alphabet Inc. — 2.26%
- Shell PLC — 2.10%
- Teck Resources Limited — 1.99%
- Heineken N.V. — 1.94%
- Resona Holdings Inc. — 1.85%
- Medtronic Public Limited Company — 1.79%
- Sanofi — 1.75%
- Methanex Corporation — 1.73%
DGEIX top 10
- DFA US Core Equity 2 Portfolio — 53.74%
- DFA US Core Equity 1 Portfolio — 17.94%
- International Core Equity 2 Portfolio — 17.93%
- Emerging Markets Core Equity 2 Portfolio — 8.62%
- DFA Real Estate Securities Portfolio — 1.34%
- DFA International Real Estate Securities — 0.44%
FAQ
What is the difference between JAKUX and DGEIX?
Which is cheaper, JAKUX or DGEIX?
Should I own both JAKUX and DGEIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.